Devyser secures a major SEK 16.8M tender in Italy with 30% growth
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for the supply of its comprehensive next-generation sequencing (NGS) tests for critical genetic markers. The tender with AOU Città Della Salute e della Scienza, Torino, Italy covers CFTR, BRCA and Thalassemia genetic testing and is valid for a period of three years. Indicative order value is estimated to amount to 16.8 million SEK.
This tender underscores Devyser’s continued excellence in delivering high-quality genetic testing solutions and its commitment to advancing precision medicine. The total contract value amounts to 16.8 million SEK, representing an approximate 30% growth compared to the previous tender. The hospital’s decision to extend the partnership with Devyser was based on the company’s proven track record of compliance and the superior performance of its NGS tests.
The tender strengthens our already strong position in the Italian market, and I am very proud of the entire team who made this happen", says CCO Theis Kipling. "This tender is another confirmation of Devyser’s position in the European healthcare market, reaffirming its role as a trusted partner for advanced genetic diagnostics.” The company remains dedicated to supporting healthcare providers with innovative and reliable solutions that enhance patient care and clinical outcomes.